HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $56

Benzinga · 3d ago
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $55 to $56.